unhelpful retraction notices – Page 4

Cancer drug paper nulled by “statistical errors”

12032 Researchers have pulled a paper about a drug used to treat pancreatic tumors due to “statistical errors.”

The 2014 paper suggested a drug that appears to treat pancreatic tumors also works in Chinese patients. We’re not exactly sure what went wrong with “A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients,” however, because the retraction note is not particularly helpful. Here’s the whole thing, published in Medical Oncology: Continue reading Cancer drug paper nulled by “statistical errors”

“Our manuscript unintentionally failed to meet academic and publication standards”

Authors of a 2014 review paper about the use of “as needed” medications by people with mental health diagnoses are retracting it, but we’re scratching our heads as to why.

The retraction appears in “The experiences of mental health professionals’ and patients’ use of pro re nata (PRN) medication in acute adult mental health care settings: a systematic review protocol of qualitative evidence,” published by The JBI Database of Systematic Reviews and Implementation Reports.

From the abstract of the paper:

Pro re nata is a Latin phrase meaning “for an unforseen need or contingency”…The authors of the systematic review found that although the practice of using “as required” medication is common there is no good evidence of whether this is the best way of helping people to be less agitated when compared to being given a regular dose of medication.

We’re not entirely sure what went wrong here. This is the full contents of the note:

Continue reading “Our manuscript unintentionally failed to meet academic and publication standards”

Authors withdraw immunology study, no reasons given

Researchers have withdrawn a 2010 article in the Journal of Biological Chemistry about an immune regulator.

The paper was pulled without any explanation (in standard JBC style). Here’s the complete notice:

This article has been withdrawn by the authors.

The study’s authors were based out of Shandong University Medical School, Jinan General Hospital of Jinan Command and Duke University Medical Center.

Two of the authors have had previous papers retracted.

Continue reading Authors withdraw immunology study, no reasons given

Two retractions cost economic historian book chapter and journal article

Francisco Gómez Camacho has lost an introduction in The Journal of Markets and Morality of a 2005 issue “for improper use of published material without attribution, as well as a a chapter in a collection of 13 scholarly essays by Brill Publishers due to “serious citation issues.”

The introduction — to a translation of another scholars’ work, Luis de Molina’s Treatise on Money — is no longer in the online version of The Journal of Markets and Morality. On the cover page, and in the table of contents, of the treatise, references to the introduction are crossed out. Where it once was in the text — page 5 of the PDF of the treatise — is a short retraction notice:

Continue reading Two retractions cost economic historian book chapter and journal article

“Data fabrication and manipulation have occurred”: Taste bud paper soured by fraud

A 2013 paper on the neurological impact of flavors has been retracted from The Journal of Neuroscience. The retraction notice offers few details (which is typical for the journal), but a statement sent to us by the last author noted that an investigation at the University of Maryland “determined that data fabrication and manipulation have occurred in this study.”

“Gustatory Stimuli Representing Different Perceptual Qualities Elicit Distinct Patterns of Neuropeptide Secretion from Taste Buds” examined the relationship between flavors and neuropeptides, molecules that send signals to the brain.

Here’s the retraction notice:

Continue reading “Data fabrication and manipulation have occurred”: Taste bud paper soured by fraud

JBC retraction on neuron development marks second for two biologists

Two biologists have retracted a second paper on the development of neurons, but that’s about all we know.

The 2007 paper from the Journal of Biological Chemistry, “The Interaction of mPar3 with the Ubiquitin Ligase Smurf2 Is Required for the Establishment of Neuronal Polarity,” concerns the role of a protein, mPar3, in neuron development. It has been cited 29 times, according to Thomson Scientific’s Web of Knowledge.

We don’t know why this one was retracted, because JBC (as usual) offered no explanation in its retraction note:

Continue reading JBC retraction on neuron development marks second for two biologists

Two crystallography papers break apart for “trivial errors,” says author

Biophysicists in India have retracted two crystallography papers describing protein binding sites following “concerns,” according to one retraction note.

The last author on both papers, however, told us he believed the retractions were the result of “trivial errors.” Although one journal praised him in its retraction note for his “positive engagement,” he said the process left him feeling “disgusted.”

One paper, “Structural Studies on Molecular Interactions between Camel Peptidoglycan Recognition Protein, CPGRP-S, and Peptidoglycan Moieties N-Acetylglucosamine and N-Acetylmuramic Acid,” was withdrawn from the Journal of Biological Chemistry in August 2014.

The second, “Mode of binding of the antithyroid drug propylthiouracil to mammalian haem peroxidases,” was retracted from Acta Crystallographica Section F this month. Here’s the retraction notice: Continue reading Two crystallography papers break apart for “trivial errors,” says author

Another author withdrawal from JBC earns another opaque notice

The authors of a 2014 study on the biochemical changes that can encourage the progression of cancer have withdrawn the paper from the Journal of Biological Chemistry.

The post from the JBC – which we’ve noted are rarely helpful – doesn’t provide any details or reason for the withdrawal. As usual, this is all we got:

Continue reading Another author withdrawal from JBC earns another opaque notice